12:00 AM
 | 
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tozadenant: Completed Phase IIb enrollment

Biotie completed enrollment of 420 patients treated with levodopa in a double-blind, placebo-controlled, international Phase IIb trial to evaluate 60, 120, 180 and 240 mg oral tozadenant twice daily. UCB has exclusive, worldwide rights from...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >